Literature DB >> 25982210

Long-term (>8 years) evaluation of progression in patients with low-pressure glaucoma.

Elif Erdem1, Alice Williams1, Sarah Driscoll Kuchar1, Michael Waisbourd1, George L Spaeth1.   

Abstract

PURPOSE: To describe the long-term clinical course of patients with low-pressure glaucoma (LPG) and to assess the risk factors for disease progression.
METHODS: The Wills Eye Glaucoma Research Center retrospectively reviewed the charts of LPG patients with documented follow-up of >8 years between 2000 and 2013. Medical records were evaluated for systemic diseases, family history of glaucoma, best-corrected visual acuity, refractive error, treatments, central corneal thickness (CCT), intraocular pressure (IOP), IOP change after pupil dilation, optic disc evaluation, visual field (VF) mean deviation (MD), VF grading, and time to progression. Progression was determined when both disc and VF appeared to have worsened.
RESULTS: From 850 charts classified as LPG between 2000 and 2013, 49 eyes of 49 patients were included in our analysis. The mean ( ± SD) follow-up time was 9.3 ( ± 1.9) years. Glaucoma progressed in 25 eyes and remained stable in 24 eyes over the follow-up period. Eyes with progression had higher peak IOP (p = 0.043). There was a trend towards progression in patients with thinner CCT (p = 0.085) and disc hemorrhage (p = 0.098). Estimated annual change in MD was -0.57 dB in the progressing group and -0.10 dB in the stable group (p<0.0001).
CONCLUSIONS: Nearly half of the patients with LPG showed glaucoma progression despite treatment after >8 years. High peak IOP was a significant risk factor for progression. Identifying patients at risk may warrant closer follow-up and more aggressive treatment in order to preserve visual function in patients with LPG.

Entities:  

Mesh:

Year:  2015        PMID: 25982210     DOI: 10.5301/ejo.5000624

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  7 in total

1.  The impact of disc hemorrhage studies on our understanding of glaucoma: a systematic review 50 years after the rediscovery of disc hemorrhage.

Authors:  Tetsuya Yamamoto
Journal:  Jpn J Ophthalmol       Date:  2018-11-21       Impact factor: 2.447

2.  Low nocturnal diastolic ocular perfusion pressure as a risk factor for NTG progression: a 5-year prospective study.

Authors:  Pushpa Raman; Nurull Bahya Suliman; Mimiwati Zahari; Michael Kook; Norlina Ramli
Journal:  Eye (Lond)       Date:  2018-03-01       Impact factor: 3.775

3.  Hydrogen sulfide supplement preserves mitochondrial function of retinal ganglion cell in a rat glaucoma model.

Authors:  Shouyue Huang; Ping Huang; Xi Shen; Yisheng Zhong; Huan Yu; Junjue Chen; Xiaohong Liu; Jing Wang
Journal:  Cell Tissue Res       Date:  2022-05-20       Impact factor: 4.051

4.  Effect of quantitative intraocular pressure reduction on visual field defect progression in normal tension glaucoma under medical therapy applying Markov model.

Authors:  Keiji Yoshikawa; Kazunori Santo; Hiroko Hizaki; Masayo Hashimoto
Journal:  Clin Ophthalmol       Date:  2018-08-30

5.  Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma.

Authors:  Keiji Yoshikawa; Shiro Mizoue; Koji Nitta; Hiroshi Onishi; Masaharu Ikeda; Akemi Mizuno; Kaori Kawazoe; Yoshiyuki Tamada; Ryuji Takeda; Shun Matsumoto
Journal:  Clin Ophthalmol       Date:  2021-07-06

6.  Long-term progression of visual field defects and related factors in medically treated normal tension glaucoma.

Authors:  Keiji Yoshikawa; Kazunori Santo; Hiroko Hizaki; Masayo Hashimoto
Journal:  Clin Ophthalmol       Date:  2018-01-31

7.  Visual Subfield Progression in Glaucoma Subtypes.

Authors:  Wei-Wen Su; Shian-Sen Hsieh; Shih-Tsung Cheng; Cheng-Wen Su; Wei-Chi Wu; Henry Shen-Lih Chen
Journal:  J Ophthalmol       Date:  2018-03-21       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.